Company intelligence / Profile preview

Avineiro

San Diego, California, United States

Ownership: Private
Development stage: Other

Overview

Avineiro is a clinical-stage biotechnology company focused on developing novel small molecule therapeutics for neurodegenerative diseases. The company's lead program, AVN-101, is a highly potent and selective Sigma-1 receptor (S1R) agonist designed to address the underlying pathology of conditions such as Amyotrophic Lateral Sclerosis (ALS) and Alzheimer's disease. By targeting the Sigma-1 receptor, Avineiro aims to restore cellular homeostasis, improve mitochondrial function, and reduce neuroinflammation. The company is currently advancing its lead candidate through early clinical development to provide transformative treatments for patients with high unmet medical needs in the CNS space.

Therapeutic areas: Neurology
Modalities: Small molecule
Industry: Biotech

Beyond the preview

Go deeper on Avineiro.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Avineiro.

Explore the full profile